Company intelligence / Profile preview

HemoBioTech

Dallas, Texas, United Stateshemotech.fr ↗

Ownership: Private
Development stage: Commercial

Overview

Initial preclinical and limited foreign clinical studies suggested safety and biological activity for HemoTech™. The company aimed to submit an IND to the FDA but had not yet begun US clinical trials as of their last public communications in ~2010. No published pivotal or late-stage results are available.

Therapeutic areas: OtherCardiovascularHematology
Modalities: BiologicRecombinant protein
Industry: Biotech

Partnerships

Paragon Biomedical (CRO)Texas Tech University Health Sciences Center

Beyond the preview

Go deeper on HemoBioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HemoBioTech.

Explore the full profile